These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 11939173)
1. High clinical inflammatory activity prior to the development of secondary progression: a prospective 5-year follow-up study. Casanova B; Coret F; Valero C; Landete L; Pascual A; Vilchez JJ Mult Scler; 2002 Feb; 8(1):59-63. PubMed ID: 11939173 [TBL] [Abstract][Full Text] [Related]
2. Natural history of secondary-progressive multiple sclerosis. Tremlett H; Yinshan Zhao ; Devonshire V Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898 [TBL] [Abstract][Full Text] [Related]
3. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802 [TBL] [Abstract][Full Text] [Related]
4. Olfactory dysfunction in multiple sclerosis: association with secondary progression. Silva AM; Santos E; Moreira I; Bettencourt A; Coutinho E; Gonçalves A; Pinto C; Montalban X; Cavaco S Mult Scler; 2012 May; 18(5):616-21. PubMed ID: 22020420 [TBL] [Abstract][Full Text] [Related]
5. Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status. Masek M; Vaneckova M; Krasensky J; Danes J; Havrdova E; Hrebikova T; Seidl Z Neuro Endocrinol Lett; 2008 Aug; 29(4):461-6. PubMed ID: 18766142 [TBL] [Abstract][Full Text] [Related]
6. Early Clinical Features, Time to Secondary Progression, and Disability Milestones in Polish Multiple Sclerosis Patients. Rzepiński Ł; Zawadka-Kunikowska M; Maciejek Z; Newton JL; Zalewski P Medicina (Kaunas); 2019 May; 55(6):. PubMed ID: 31159275 [No Abstract] [Full Text] [Related]
7. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis. Gava G; Bartolomei I; Costantino A; Berra M; Venturoli S; Salvi F; Meriggiola MC Fertil Steril; 2014 Jul; 102(1):116-22. PubMed ID: 24794311 [TBL] [Abstract][Full Text] [Related]
8. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis. Muris AH; Rolf L; Broen K; Hupperts R; Damoiseaux J; Smolders J J Steroid Biochem Mol Biol; 2016 Nov; 164():254-257. PubMed ID: 26598277 [TBL] [Abstract][Full Text] [Related]
11. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis. Calabrese M; Rocca MA; Atzori M; Mattisi I; Favaretto A; Perini P; Gallo P; Filippi M Ann Neurol; 2010 Mar; 67(3):376-83. PubMed ID: 20373349 [TBL] [Abstract][Full Text] [Related]
12. Does pregnancy alter the long-term course of multiple sclerosis? Karp I; Manganas A; Sylvestre MP; Ho A; Roger E; Duquette P Ann Epidemiol; 2014 Jul; 24(7):504-8.e2. PubMed ID: 24935463 [TBL] [Abstract][Full Text] [Related]
14. The role of endogenous antiradical protective system in multiple sclerosis. Davitashvili D; Beridze M; Shakarishvili R; Kiziria M; Sanikidze T Georgian Med News; 2012 Apr; (205):11-9. PubMed ID: 22665726 [TBL] [Abstract][Full Text] [Related]
15. Predicting the severity of relapsing-remitting MS: the contribution of cross-sectional and short-term follow-up MRI data. Enzinger C; Fuchs S; Pichler A; Wallner-Blazek M; Khalil M; Langkammer C; Ropele S; Fazekas F Mult Scler; 2011 Jun; 17(6):695-701. PubMed ID: 21228028 [TBL] [Abstract][Full Text] [Related]
16. Management of worsening multiple sclerosis with mitoxantrone: a review. Fox EJ Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460 [TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736 [TBL] [Abstract][Full Text] [Related]